Navigation Links
Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis

psing forms of MS. TYSABRI increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability. Patients should be monitored at regular intervals for any new or worsening signs or symptoms suggestive of PML Because of the increased risk of PML, TYSABRI is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate MS therapies. It is available in the US only through a restricted distribution program called the TOUCH Prescribing Program. According to product labeling, after two years, TYSABRI treatment led to a 67% relative reduction (p<0.001) in the annualized relapse rate compared to placebo and reduced the relative risk of disability progression by 42% (p<0.001). TYSABRI treatment also resulted in sustained and statistically significant reductions in brain lesion activity as measured by MRI. Changes in MRI findings often do not correlate with changes in the clinical status of patients (e.g., disability progression). The prognostic significance of the MRI findings in these studies has not been evaluated.

In the European Union, TYSABRI is indicated as a single disease-modifying therapy in highly active relapsing-remitting MS patients. Because of the increased risk of PML, it is for patients with high disease activity despite treatment with a beta-interferon or in patients with rapidly evolving severe relapsing-remitting MS.

According to product labeling in the EU, after two years, TYSABRI treatment led to a 68% relative reduction (p<0.001) in the annualized relapse rate compared to placebo and reduced the relative risk of disability progression by 42-54% (p<0.001).

Serious adverse events that occurred in TYSABRI-treated patients included hypersensitivity reactions (e.g., anaphylaxis), infections, depression and gallstones. In MS trials, the incidence and rate of other serious and common adverse events, including the overall incidence and rat
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:12/22/2014)... , Dec. 22, 2014 TWi Biotechnology, ... of Allowance for AC-201, TWi Biotechnology,s lead drug ... China for patent application ... pharmaceutically acceptable salts, active metabolite for treatment of ... methods of treatment using AC-201 for type II ...
(Date:12/19/2014)... 19, 2014  Advanced Medical Isotope Corporation ("AMIC") ... primarily in the development of brachytherapy devices and ... announced that a Life Sciences Discovery Fund (LSDF) ... which AMIC is the commercialization partner.  The award ... the proposal titled "Optimized Injectable Radiogels for High-dose ...
(Date:12/19/2014)... -- Monarch America Inc. (OTCQB: CANK) ("Monarch America" or the ... this review of the Company,s recent achievements and strategic ... this past year, we achieved many of our early ... say that Monarch America is in a stronger and ... stated Eric Hagen , CEO of Monarch America ...
Breaking Medicine Technology:TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3
... conducted by Nobel laureate Paul Greengard, Medical Director of The ... , Dr. Jennifer L. Warner-Schmidt in New York and colleagues ... that the brain protein called p11 could lead pharmaceutical companies ... days rather than the weeks or even months required by ...
... NEW BRUNSWICK, N.J., March 23 Each year in the ... lymphoma or myeloma. These new cases account for 10 ... per year. For several types of leukemia, the survival ... That,s why James M. Golubieski, president of Foundation Venture Capital ...
Cached Medicine Technology:Key Protein May Lead to Faster Acting Anti-Depression Drugs 2Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments 2
(Date:12/22/2014)... Harrisburg, NC (PRWEB) December 22, 2014 ... contain the current Ebola virus epidemic are ... by U.S. government agencies, nongovernmental organizations (NGOs) ... solutions remains ongoing, healthcare workers, emergency responders, ... advanced technologies such as the CmTP ...
(Date:12/22/2014)... new vaccine created to fight an illness similar to ... and even humans from similar brain infections, researchers report. ... becoming infected by the incurable brain disorder known as ... Dec. 21 online edition of the journal Vaccine ... particles known as prions that go rogue. Prion ...
(Date:12/22/2014)... December 22, 2014 The Bob ... ever, having invested more than $5 million in ... veterans and their families. , This includes $1.3 ... dozen nonprofits, helping with: veteran entrepreneurship; community impact; ... life-coaches for severely injured veterans. , “The needs ...
(Date:12/22/2014)... Explorys, the leader in big data-driven healthcare ... Greg Yarrington as Vice President of Operations, Adam Wallace ... Vice President of Solutions. These new leaders are part ... 2015 to support client demand for the company’s big ... growth of its partner network. , Since the ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Give a ... season, the gift of health and vitality. , For ... its three top-selling anti-aging formulas in special Holiday Wellness ... rush delivery. , Each bottle contains cutting-edge, proven ... that don't work as well as we age. ...
Breaking Medicine News(10 mins):Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2
... for bona fide media presenting official press credentials , ... facilities & IT support, English, Swedish, Spanish, German, and ... language is English] News briefings will be ... hrs CEST Monday 4 July (English), 14.00 hrs CEST ...
... more likely to suffer surgical site infections (SSIs) if the ... July issue of BJS, the British Journal of Surgery ... major abdominal surgery, exploring demographic parameters, the duration of the ... patients (17 per cent) developed SSIs and the only variable ...
... patients survive longer than Caucasians no matter how many drugs ... apparent both before and after the introduction of targeted therapies ... June issue of the Journal of Thoracic Oncology . ... of lung cancer, the non-small cell type, have a better ...
... Although gynecologic cancers account for only 10 percent of ... for 20 percent of all female cancer survivors. Because ... important to detect recurrence. The Clinical Practice Committee of ... Clinical Document outlining their expert recommendations for cancer surveillance, ...
... prior authorization for imaging services using proprietary algorithms to ... have the potential to either increase or decrease societal ... of the Journal of the American College of ... widely used by private payers to manage the utilization ...
... TUESDAY, May 31 (HealthDay News) -- Although many older diabetics ... fractures as people with osteoporosis, a new study finds. ... test to look for signs of bone loss and osteoporosis, ... with type 2 diabetes has been a question, according to ...
Cached Medicine News:Health News:European Society of Human Reproduction and Embryology Annual Meeting July 3-6, 2011, Stockholm 2Health News:European Society of Human Reproduction and Embryology Annual Meeting July 3-6, 2011, Stockholm 3Health News:Noisy operations associated with increased infections after surgery 2Health News:Asian lung cancer patient survival exceeds Caucasians' on multiple regimens 2Health News:SGO sets new standards to monitor recurrence of gynecologic cancer more effectively 2Health News:Radiology benefit managers adversely affect referring physicians, study suggests 2Health News:In Diabetics, Good Scores on Bone Tests May Not Rule Out Risk 2Health News:In Diabetics, Good Scores on Bone Tests May Not Rule Out Risk 3
For the qualitative detection of human Chorionic Gonadotrophin (hCG) in urine specimens...
For the qualitative detection of human Chorionic Gonadotrophin (hCG) in urine specimens...
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: